Invention Grant
- Patent Title: Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment
-
Application No.: US16303861Application Date: 2017-05-30
-
Publication No.: US10668166B2Publication Date: 2020-06-02
- Inventor: Ain Uustare , Ivan Ogibalov , Olga T{hacek over (s)}ubrik , Andrus Tasa , Uno Mäeorg , Ago Rinken
- Applicant: Toxinvent Oü
- Applicant Address: EE Tartu
- Assignee: Toxinvent Ou
- Current Assignee: Toxinvent Ou
- Current Assignee Address: EE Tartu
- Agency: Ballard Spahr LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@6be41e01 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@6bf573d1
- International Application: PCT/EP2017/062989 WO 20170530
- International Announcement: WO2017/207540 WO 20171207
- Main IPC: C07D498/04
- IPC: C07D498/04 ; A61K47/68 ; A61K31/424 ; C07H15/252
Abstract:
The present invention relates to novel anthracycline derivatives comprising two oxazolidine cycles and the preparation of said anthracycline derivatives. Furthermore, antibody-drug conjugates (ADCs) comprising the novel anthracycline derivatives and the use of such ADCs in the prevention and treatment of cancer are disclosed.
Public/Granted literature
- US20190262464A1 ANTIBODY-DRUG-CONJUGATES COMPRISING NOVEL ANTHRACYCLINE-DERIVATIVES FOR CANCER TREATMENT Public/Granted day:2019-08-29
Information query
